greeksoup/ stock research

Gentherm Inc.: Q1 FY2026 earnings call

What management said about Q1 FY2026, from the documents filed with the SEC on 23 April 2026: press release. Guidance figures: 3 kept. The quarter’s numbers.

Key takeaways

  • Record revenue reached $393.7 million: Product revenues increased 11.3% to $393.7 million from $353.9 million, or 7.2% excluding foreign currency translation. CEO stated the team executed well with tangible results from establishing a more robust operating system. Source
  • Adjusted EBITDA margin improved 140 basis points: Adjusted EBITDA was $49.3 million or 12.5% of revenue versus $39.3 million or 11.1% prior year. Adjusted diluted EPS rose to $0.84 from $0.51 year-over-year. Source
  • Climate and Comfort Solutions outpaced market 14 percentage points: Automotive Climate and Comfort Solutions grew 13.6% year-over-year, or 9.8% ex-FX, outperforming S&P Global light vehicle production in relevant markets by 14 percentage points, demonstrating market share gains. Source
  • Secured $395 million in new automotive awards: During Q1, Gentherm secured $395 million in new automotive awards, building forward pipeline and reflecting customer confidence in the thermal and comfort platform. Source
  • FDA submission filed for patient warming system: Company submitted FDA 510(k) Class II premarket notification for ThermAffyx Patient Safety System, an integrated patient warming and securement system leveraging automotive thermal technology, with revenue expected Q3 2026. Source
  • Transformational combination announced on track to close: Company announced planned combination with Modine Performance Technologies establishing a leader in thermal and precision flow management solutions. Transaction remains on track to close by end of 2026. Source
  • Modine deal creates stronger platform for growth: CEO described the combination as a strategic inflection point creating a stronger enterprise with expanded product portfolio, broader end market exposure, and clear value creation opportunities. Source
  • Net leverage improved to 0.2x on debt reduction: Net leverage declined to approximately 0.2x versus 0.6x in prior year. Net debt stood at $41.6 million with total liquidity of $455.5 million, showing strengthened balance sheet. Source

“Our team executed well in the first quarter. We started seeing the tangible results from our efforts to establish a more robust operating system which drove improved performance on stronger volumes. We also continued progressing our organic growth initiatives in both home and office, and medical markets.”

Bill Presley, President and CEO

Guidance

AreaPeriodFigureAgainst last quarter
Product Revenues Sourcefull year 2026$1.5B - $1.6BKept
Adjusted EBITDA Sourcefull year 2026$175M - $195MKept
Adjusted Free Cash Flow Sourcefull year 2026$80M - $100MKept

What changed from last quarter

  • New: Gentherm announced a transformational combination with Modine Performance Technologies on track to close by year-end 2026, establishing a leader in thermal and precision flow management across multiple end markets. Source
  • New: Company submitted FDA 510(k) Class II premarket notification for ThermAffyx Patient Safety System, an integrated patient warming and securement system leveraging automotive thermal technology, with revenue expected Q3 2026. Source
  • New: Delivered first home and office solutions to KUKA Home in Asia, extending scalable technology platforms into new geographic and product markets. Source

Quarterly Results and Margin Expansion

  • Record revenue reached $393.7 million: Product revenues increased 11.3% to $393.7 million from $353.9 million, or 7.2% excluding foreign currency translation. CEO stated the team executed well with tangible results from establishing a more robust operating system. Source
  • Adjusted EBITDA margin improved 140 basis points: Adjusted EBITDA was $49.3 million or 12.5% of revenue versus $39.3 million or 11.1% prior year. Adjusted diluted EPS rose to $0.84 from $0.51 year-over-year. Source
  • Gross margin expanded on operating leverage: Gross margin increased to 24.7% from 24.4% prior year. Operating leverage and net material performance drove gains, partially offset by annual customer price reductions and higher labor costs. Source

Automotive Market Share and Pipeline

  • Climate and Comfort Solutions outpaced market 14 percentage points: Automotive Climate and Comfort Solutions grew 13.6% year-over-year, or 9.8% ex-FX, outperforming S&P Global light vehicle production in relevant markets by 14 percentage points, demonstrating market share gains. Source
  • Secured $395 million in new automotive awards: During Q1, Gentherm secured $395 million in new automotive awards, building forward pipeline and reflecting customer confidence in the thermal and comfort platform. Source

“This quarter also marked a strategic inflection point for Gentherm. Our announced combination with Modine Performance Technologies creates a stronger enterprise, with an expanded product portfolio, broader end market exposure, and clear value creation opportunities.”

Bill Presley, President and CEO

Medical and Adjacent Market Initiatives

  • FDA submission filed for patient warming system: Company submitted FDA 510(k) Class II premarket notification for ThermAffyx Patient Safety System, an integrated patient warming and securement system leveraging automotive thermal technology, with revenue expected Q3 2026. Source
  • First home and office solutions delivered in Asia: Gentherm delivered first home and office climate solutions to KUKA Home in Asia, extending scalable technology platforms into new geographic and end markets beyond automotive. Source

Modine Combination and Strategic Transformation

  • Transformational combination announced on track to close: Company announced planned combination with Modine Performance Technologies establishing a leader in thermal and precision flow management solutions. Transaction remains on track to close by end of 2026. Source
  • Modine deal creates stronger platform for growth: CEO described the combination as a strategic inflection point creating a stronger enterprise with expanded product portfolio, broader end market exposure, and clear value creation opportunities. Source
  • 2026 guidance excludes deal impact: Full year 2026 financial guidance does not reflect any impact from the planned Modine combination, as the transaction is expected to close later in the year. Source

Balance Sheet and Cash Generation

  • Operating cash flow negative but improved year-over-year: Operating cash flow was negative $5.0 million compared to negative $13.3 million in prior year quarter. Negative Q1 cash flow is typical due to seasonal working capital timing. Source
  • Net leverage improved to 0.2x on debt reduction: Net leverage declined to approximately 0.2x versus 0.6x in prior year. Net debt stood at $41.6 million with total liquidity of $455.5 million, showing strengthened balance sheet. Source
  • Free cash flow negative but improving trend: Free cash flow was negative $10.7 million versus negative $24.5 million prior year, showing improvement despite seasonal Q1 headwinds. Adjusted free cash flow was negative $2.6 million versus negative $15.5 million prior year. Source

Coming up, as management said on 23 April 2026

  • ThermAffyx FDA product revenue beginning Q3 2026: Following FDA 510(k) Class II submission for ThermAffyx Patient Safety System, the company expects revenue to begin in Q3 2026 from this integrated patient warming and securement system. Source
  • Modine combination closing targeted for end of 2026: The planned combination with Modine Performance Technologies remains on track to close by the end of 2026, with parties intending to file relevant SEC materials including Form S-4 registration statement. Source
  • Home and office market platform expansion underway: Following initial deliveries to KUKA Home in Asia during Q1, Gentherm continues scaling climate and comfort technology platforms into adjacent home and office markets with expanding customer relationships. Source

Risks management discussed

  • Financial: Tariff levels and trade policies could impact product costs and margins, with current guidance based on tariffs in effect as of April 2026. Source
  • Demand: Light vehicle production in the company's relevant markets is expected to decline at a low single-digit rate in 2026, creating a production volume headwind. Source
  • Operational: Customer price reductions and higher labor costs pressured gross margin in Q1 and may continue offsetting operating leverage in subsequent quarters. Source
  • Regulatory: Modine combination closing conditions including regulatory approvals must be satisfied for the transaction to complete by end of 2026. Source

Earlier plans management reported on

  • On track: The planned combination with Modine Performance Technologies announced in Q1 2026 remains on track to close by the end of 2026. Source
  • On track: Following FDA 510(k) Class II submission for ThermAffyx Patient Safety System, revenue generation is expected to commence in Q3 2026. Source
  • On track: Company maintained full year 2026 product revenue guidance of $1.5B-$1.6B as of April 23, 2026, unchanged from February guidance. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.